Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain
Starting soon · Not applicable
Conditions studied: Herpes Zoster, Zoster-Associated Pain, Postherpetic Neuralgia, Neuropathic Pain, Acute Pain
In brief
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.
Key facts
- Study ID
- NCT07569978
- Run by
- Nakhia Impex LLC
- People needed
- 30
- Starts
- 2026-05-01
- Expected to finish
- 2026-07-10
- Last updated by the study team
- 2026-05-08
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18-85 years, male or female
- Clinically diagnosed with herpes zoster-associated pain (acute ZAP or PHN)
- Baseline pain NRS score ≥5
- Ability to understand and complete NRS assessments
- Signed written informed consent
You may not qualify if…
- Acute bacterial skin infection at the application site
- Use of topical analgesics or antiviral therapy within 24 hours
- Systemic analgesic use within 6 hours
- Known hypersensitivity to hyaluronan or gel components
- Pregnant or lactating women
- Severe systemic disease or malignant tumor
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.